Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTIG65Q)

DTT Name Voltage-gated sodium channel (Nav)
Gene Name Nav
DTT Type
Successful target
 [1]
BioChemical Class
Voltage-gated ion channel
UniProt ID
NOUNIPROTAC
TTD ID
T72065

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
8 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cenobamate DM8KLU9 Complex partial seizure 8A68.0 Approved [2]
Eslicarbazepine DMZREFQ Seizure disorder 8A6Z Approved [1]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [3]
Lacosamide DMVM6QR Convulsion 8A68.Z Approved [1]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [3]
Propafenone DMPIBJK Tachyarrhythmias BC71 Approved [3]
Tetrodotoxin DMWMPRG Bacterial infection 1A00-1C4Z Approved [1]
Tocainide DMYNMDP Ventricular arrhythmias BC71 Approved [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Approved Drug(s)
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Evenamide DMWB94K Schizophrenia 6A20 Phase 2 [4]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Barucainide DMTMS3L Heart arrhythmia BC65 Terminated [5]
------------------------------------------------------------------------------------

References

1 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2 Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Clinical pipeline report, company report or official report of Newron Pharmaceuticals.
5 Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60.